44c, page-3

Just heard that they were originally only after 2mill or so but demand was so overwhelming that they took 5 mill plus scaled back significantly.

Then for them to announce that in recent discussions with and note this, Global Pharmaceutical companies, Ie multinationals and more than one they reccommend that CBZ start scaling up as they need more Xtoll...if this doesn't say that the chances of the drug being a success are extremely high then what does.

Note that the previous trials have shown less side effects than any other major drug on the market(considering that the side effects of these other players are illnesses such as cancers) and that patients who recorded a 20% or more improvement was greater than any other drug on the market.

Humira which has currently the best RA drug in the market (for patients recording a 20% or more improvement) has revenues of US4.5 Billion in 2008, Enbrel is next with a US 6.5 billion annual revenue and Remicade is next with US 6.2 bill in annual revenue.Please note that CBIO's drug is also cheapest of the 4 to manufacture.

The stock held up extremely well considering the size of the placement and the overall market, this bodes very well for the short term.

?The placement was strongly supported by new and existing Professional and Sophisticated investors, and due
to the strong demand final allocations were scaled back.
In most recent discussions with global pharmaceutical companies it was recommended that CBio commence
drug manufacturing scale‐up of XToll
?
for the purposes of preparing for the onward stages of clinical
development including long-term toxicology studies and a dose optimisation Phase IIb clinical trial in humans,
in the event a potential licensing or collaboration agreement is reached in the future. These funds position the
company to commit to manufacturing scale-up.